Skip to main content
    M

    Medpace Holdings Inc (MEDP)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $648.20
    -5.74 (-0.88%)

    Market Cap: $18.29B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Medpace Holdings Inc (MEDP) Earnings: Report Dates and Results

    Updated Oct 21, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Medpace Holdings (MEDP) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Medpace Holdings reported EPS of $4.84, above the $4.45 estimate. It beat the EPS estimate in each of the last 13 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +12.93%
    Streak
    13 Q

    Upcoming Estimates

    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$4.93
    Range$4.67 - $5.20
    14 analysts
    Revenue Consensus
    $732.76M
    Range$695.80M - $761.25M
    14 analysts
    Reports Apr 20, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$4.66
    Range$4.50 - $4.91
    7 analysts
    EPS Estimate DriftChange to current
    90d ago$4.61+1.0%
    60d ago$4.61+1.0%
    30d ago$4.61+1.0%
    7d ago$4.59+1.4%
    Current$4.66
    Revenue Consensus
    $726.89M
    Range$713.67M - $742.22M
    8 analysts

    Next Report

    MEDP has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 5.6% above the $4.67 reported for the quarter ended Dec 31, 2025.

    MEDP Earnings Call

    The latest MEDP earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, MEDP beat 36, missed 3 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $716.00M, up 8.5% from $659.90M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$4.84$4.45$4.31 - $4.69+8.76%Beat+25.4%81 up, 0 downOct 21, 2026$716.00M
    Jun 30, 2026$4.25$4.08$3.71 - $4.35+4.17%Beat+37.1%93 up, 5 downJul 22, 2026$707.33M
    Mar 31, 2026$4.28$3.96$3.47 - $4.40+8.08%Beat+16.6%81 up, 0 downApr 22, 2026$706.60M
    Dec 31, 2025$4.67$4.18$4.12 - $4.37+11.72%Beat+26.9%50 up, 1 downFeb 9, 2026$708.45M
    Sep 30, 2025$3.86$3.57$3.38 - $3.66+8.12%Beat+28.2%62 up, 0 downOct 22, 2025$659.90M
    Jun 30, 2025$3.10$3.00$2.76 - $3.28+3.33%Beat+12.3%61 up, 2 downJul 21, 2025$603.31M
    Mar 31, 2025$3.67$3.07$3.00 - $3.28+19.54%Beat+14.0%41 up, 1 downApr 21, 2025$558.57M
    Dec 31, 2024$3.68$3.12$3.09 - $3.17+18.12%Beat+49.6%32 up, 0 downFeb 10, 2025$536.59M
    Sep 30, 2024$3.01$2.87N/A+4.88%Beat+34.4%80 up, 2 downOct 21, 2024$533.32M
    Jun 30, 2024$2.76$2.63N/A+4.94%Beat+41.5%81 up, 0 downJul 22, 2024$528.10M
    Mar 31, 2024$3.22$2.49$2.43 - $2.54+29.32%Beat+41.2%60 up, 0 downApr 22, 2024$511.04M
    Dec 31, 2023$2.46$2.22$2.20 - $2.25+10.81%Beat+16.0%50 up, 0 downFeb 12, 2024$498.40M
    Sep 30, 2023$2.24$2.19N/A+2.28%Beat+8.2%51 up, 0 downOct 23, 2023$492.50M
    Jun 30, 2023$1.95$2.00N/A-2.50%Miss+31.8%51 up, 0 downJul 24, 2023$460.87M
    Mar 31, 2023$2.28$1.88N/A+21.28%Beat+33.3%40 up, 0 downApr 24, 2023$434.07M
    Dec 31, 2022$2.12$1.79$1.74 - $1.82+18.44%Beat+60.6%50 up, 0 downFeb 13, 2023$394.10M
    Sep 30, 2022$2.07$1.54N/A+34.42%Beat+56.8%51 up, 0 downOct 24, 2022$383.74M
    Jun 30, 2022$1.48$1.39$1.16 - $1.42+6.47%Beat+35.8%51 up, 1 downJul 25, 2022$351.21M
    Mar 31, 2022$1.71$1.31N/A+30.53%Beat+44.9%40 up, 0 downApr 25, 2022$330.95M
    Dec 31, 2021$1.32$1.25$1.22 - $1.27+5.60%Beat-2.2%40 up, 0 downFeb 14, 2022$308.55M
    Sep 30, 2021$1.32$1.12N/A+17.86%Beat+15.8%4N/AOct 25, 2021$295.57M
    Jun 30, 2021$1.09$1.03$0.97 - $1.04+5.83%Beat+60.3%6N/AJul 26, 2021$278.29M
    Mar 31, 2021$1.18$1.07N/A+10.28%Beat+47.5%6N/AApr 26, 2021$259.96M
    Dec 31, 2020$1.35$1.24$1.20 - $1.30+8.87%Beat+58.8%6N/AFeb 15, 2021$259.68M
    Sep 30, 2020$1.14$1.16N/A-1.72%Miss+60.6%6N/AOct 26, 2020$230.37M
    Jun 30, 2020$0.68$0.44$0.19 - $0.54+54.55%Beat-16.0%7N/AJul 27, 2020$205.00M
    Mar 31, 2020$0.80$0.75$0.69 - $0.83+6.67%Beat+25.0%4N/AApr 28, 2020$230.88M
    Dec 31, 2019$0.85$0.75$0.74 - $0.76+13.33%Beat+11.8%6N/AFeb 24, 2020$229.89M
    Sep 30, 2019$0.71$0.71$0.64 - $0.750.00%In line+6.0%6N/AOct 28, 2019$216.24M
    Jun 30, 2019$0.81$0.64$0.58 - $0.81+26.56%Beat+32.8%6N/AJul 29, 2019$214.10M
    Mar 31, 2019$0.64$0.61$0.54 - $0.65+4.92%Beat+16.4%7N/AApr 29, 2019$200.74M
    Dec 31, 2018$0.76$0.67$0.60 - $0.73+13.43%Beat+94.9%5N/AFeb 25, 2019$192.12M
    Sep 30, 2018$0.67$0.63$0.59 - $0.65+6.35%Beat+67.5%5N/AOct 29, 2018$179.25M
    Jun 30, 2018$0.61$0.43$0.36 - $0.45+41.86%Beat+60.5%7N/AJul 30, 2018$170.14M
    Mar 31, 2018$0.55$0.44$0.42 - $0.45+25.00%Beat+61.8%7N/AApr 30, 2018$163.08M
    Dec 31, 2017$0.39$0.38$0.37 - $0.41+2.63%Beat+11.4%7N/AFeb 26, 2018$112.68M
    Sep 30, 2017$0.40$0.36$0.35 - $0.37+11.11%Beat0.0%7N/AOct 30, 2017$110.64M
    Jun 30, 2017$0.38$0.30$0.29 - $0.31+26.67%Beat-15.6%6N/AJul 31, 2017$106.22M
    Mar 31, 2017$0.34$0.37N/A-8.11%MissN/AN/AN/AMay 1, 2017$106.61M
    Dec 31, 2016$0.35$0.34N/A+2.94%BeatN/AN/AN/AFeb 27, 2017$108.24M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $15.30, up 20.7% from the year before. It was $1.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$15.30+20.7%
    Dec 31, 2024$12.67+41.9%
    Dec 31, 2023$8.93+21.0%
    Dec 31, 2022$7.38+50.3%
    Dec 31, 2021$4.91+23.7%
    Dec 31, 2020$3.97+31.9%
    Dec 31, 2019$3.01+16.2%
    Dec 31, 2018$2.59+71.5%
    Dec 31, 2017$1.51+25.8%
    Dec 31, 2016$1.20N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,200 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,19814
    2026Q2Jun 30, 20264,40114
    2026Q1Mar 31, 20265,10816
    2025Q4Dec 31, 20255,60916
    2025Q3Sep 30, 20255,06015
    2025Q2Jun 30, 20256,71415
    2025Q1Mar 31, 20255,85014
    2024Q4Dec 31, 20244,92914

    2026Q3 Earnings Call

    Opening remarks

    Lauren Morris Director of Investor Relations Good morning, and thank you for joining Medpace's third quarter 2026 Earnings Conference Call. Also on the call today are our CEO, August James Troendle, and our CFO, Kevin Brady. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 2000. These statements involve inherent assumptions, with known and unknown risks and uncertainties, as well as other important factors that could cause actual results to differ materially from our current expectations. These factors are discussed in our Form 10-Ks and other filings with the SEC. Please note that we assume no obligation to update forward-looking statements, even if estimates change. Accordingly, you should not rely on any of today's forward-looking statements as representing our views as of any date after today. During this call, we will also be referring to certain non-GAAP financial measures. These non-GAAP measures are not superior to or a replacement for the comparable GAAP measures, but we believe these measures help investors gain a more complete understanding of results. A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available in the earnings press release and earnings call presentation slides provided in connection with today's call. The slides are available in the Investor Relations section of our website at investor.medpace.com. With that, I would now like to turn the call over to August Troendle.

    August James Troendle CEO Thanks, Lauren. Good morning, everyone. The business environment remains strong in the third quarter of 2026. We saw high-quality RFP activity, strong initial award notifications, and a good win rate. Net new business awards reached an all-time high in the quarter, and our last 12-month closing awards growth was 23.9%. We will provide guidance for 2027 at the end of our Q4 reporting. At the time of our Q4 reporting in February, however, we see no large disconnect between analyst consensus estimates and our current modeling of 2027. Kevin will now review our financial results for Q3 and our updated 2026 guidance.

    Kevin Brady CFO Thank you, and good morning to everyone listening in. Revenue was $716 million in the third quarter of 2026. This represented a year-over-year increase of 8.5%. Revenue for the nine months ended September 30, 2026, was $2.13 billion, an increase of 16.9%. EBITDA of $172.1 million increased 16% compared to $148.4 million in the third quarter of 2025. Year-to-date EBITDA was $474.9 million, an increase of 19.5% from the comparable prior-year period. EBITDA margin for the third quarter was 24%, compared to 22.5% in the prior-year period. EBITDA margins benefited from lower reimbursable costs.

    Frequently Asked Questions About MEDP

    When is Medpace Holdings's next earnings date?

    Medpace Holdings's next earnings report is expected for Feb 8, 2027.

    Did MEDP beat earnings estimates last quarter?

    Yes. Medpace Holdings reported EPS of $4.84 for the quarter ended Sep 30, 2026, above the $4.45 estimate, a 8.76% surprise.

    What EPS do analysts expect from MEDP next quarter?

    The consensus EPS estimate for Medpace Holdings for the quarter ending Dec 31, 2026 is $4.93 from 14 analysts, with estimates from $4.67 to $5.20.

    How often does MEDP beat earnings estimates?

    Medpace Holdings beat the EPS estimate in each of the last 13 quarters, with an average surprise of +10.31%.